Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asengeprast - Certa Therapeutics

Next Previous
Drug Profile

Asengeprast - Certa Therapeutics

Alternative Names: FT-011; SHP 627

Latest Information Update: 30 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fibrotech Therapeutics; University of Melbourne
  • Developer Certa Therapeutics; Shire
  • Class Alkynes; Anthranilic acids; Antifibrotics; Antiglaucomas; Caffeic acids; Heart failure therapies; Skin disorder therapies; Small molecules; Urologics
  • Mechanism of Action GPR68 protein antagonists; Platelet-derived growth factor inhibitors; TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Focal segmental glomerulosclerosis; Systemic scleroderma
  • Phase I Renal failure
  • Discontinued Diabetic nephropathies; Glaucoma; Heart failure; Kidney disorders

Most Recent Events

  • 19 Dec 2024 OccuRx has been acquired and merged into Certa Therapeutics
  • 22 Jul 2024 FT 011 receives Orphan Drug status for Systemic scleroderma in European Union
  • 19 Feb 2024 FT 011 receives Fast track status from the US FDA for Systemic scleroderma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top